BIONi010-C-13
BIONi010-C + NGN2 #I7-26
Gene-edited iPSC line
At European Collection of Authenticated Cell Cultures (ECACC)
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg Name | BIONi010-C-13 |
| Alternative name(s) |
BIONi010-C + NGN2 #I7-26
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Notes | No larger chromosomal aberrations to be reported. Chr22: 1,4Mbp duplication in q11.23 |
Provider |
|
| Depositor | Bioneer (BION) |
| Owner | Bioneer (BSC) |
| Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
| Derivation country | Denmark |
External Databases |
|
| hPSCreg | BIONi010-C-13 |
| BioSamples | SAMEA103988285 |
| ECACC | 66540561 |
| Cellosaurus | CVCL_RF90 |
| CLO | CLO_0102727 |
| Wikidata | Q54796758 |
General Information |
|
| Publications | View all related publications on hPSCreg (5) |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information#
General Donor Information |
|
| Sex | male |
| Ethnicity | Black or African-American |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA3105780 |
hIPSC Derivation#
General |
|
|
The source cell information can be found in the parental cell line
BIONi010-C.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
Latest released batch |
|
| Culture medium | mTeSR1 |
| Passage method | EDTA |
| Surface coating | Matrigel |
| O2 concentration | 21 |
| CO2 concentration | 5 |
| Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 18 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
Morphology pictures
Differentiation Potency
In vitro directed differentiation
Morphology
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Sterility |
|
| Inoculation for microbiological growth | No Contaminants Detected |
| Mycoplasma | Not Detected |
| Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Genetic Modification#
| Genetic modifications not related to a disease |
|